Abstract
Nonunions and delayed unions are among the more challenging clinical and surgical entities an orthopaedic surgeon must manage. Effective strategies that address these complex problems are in need and gene therapy represents a potential therapeutic option. Among the many properties that bone morphogenetic proteins (BMPs) possess, their potent osteoinductive effects make them attractive growth factors for use in gene therapy to address large bony defects. Gene therapy enables a sustained production of BMP to be achieved at specific sites of interest and represents a significant advantage over protein-delivery based systems. Viruses are effective vectors for delivering BMP cDNA because they are designed to efficiently infect cells and transmit genetic material. However, safety concerns such as immune system activation and insertional mutagenesis represent drawbacks that may limit their clinical efficacy. Nonviral vectors are emerging as attractive candidates for gene delivery since they avoid many of the safety issues seen with viral vectors but have lower genetic transfer efficiency. A wide variety or preclinical studies of bone regeneration using BMPs have demonstrated the efficacy of both in vivo and ex vivo gene therapy techniques and these will be explored in this review article.
Keywords: Gene therapy, BMP, in vivo, ex vivo, critical defect.
Current Pharmaceutical Design
Title:Gene Therapy for Bone Regeneration
Volume: 19 Issue: 19
Author(s): Michael J. Pensak and Jay R. Lieberman
Affiliation:
Keywords: Gene therapy, BMP, in vivo, ex vivo, critical defect.
Abstract: Nonunions and delayed unions are among the more challenging clinical and surgical entities an orthopaedic surgeon must manage. Effective strategies that address these complex problems are in need and gene therapy represents a potential therapeutic option. Among the many properties that bone morphogenetic proteins (BMPs) possess, their potent osteoinductive effects make them attractive growth factors for use in gene therapy to address large bony defects. Gene therapy enables a sustained production of BMP to be achieved at specific sites of interest and represents a significant advantage over protein-delivery based systems. Viruses are effective vectors for delivering BMP cDNA because they are designed to efficiently infect cells and transmit genetic material. However, safety concerns such as immune system activation and insertional mutagenesis represent drawbacks that may limit their clinical efficacy. Nonviral vectors are emerging as attractive candidates for gene delivery since they avoid many of the safety issues seen with viral vectors but have lower genetic transfer efficiency. A wide variety or preclinical studies of bone regeneration using BMPs have demonstrated the efficacy of both in vivo and ex vivo gene therapy techniques and these will be explored in this review article.
Export Options
About this article
Cite this article as:
Pensak Michael J. and Lieberman Jay R., Gene Therapy for Bone Regeneration, Current Pharmaceutical Design 2013; 19 (19) . https://dx.doi.org/10.2174/1381612811319190012
DOI https://dx.doi.org/10.2174/1381612811319190012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nano Hydroxyapatite (nano-HAp): A Potential Bioceramic for Biomedical Applications
Current Nanomaterials Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Recent Advances in Metal-Organic Frameworks as Anticancer Drug Delivery Systems: A Review
Anti-Cancer Agents in Medicinal Chemistry Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Craniofacial Fibrous Dysplasia Involvements of Mccune-Albright Syndrome: A Review with an Additional Case
Current Medical Imaging Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for Sustained and Localized Delivery
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Field of Anticancer Platinum Complexes
Recent Patents on Anti-Cancer Drug Discovery The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry miR-375 Inhibits the Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma by Targeting XPR1
Current Gene Therapy Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology